NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gern.
The investigation concerns whether Geron and certain of its officers and/or directors have violated Federal Securities Laws.
On September 27, 2018, before market hours, Geron revealed that "Janssen Biotech, Inc. (Janssen) has terminated the 2014 Collaboration and License Agreement (CLA) with the Company. Janssen stated in their press release issued today that they made this decision as the result of a strategic portfolio evaluation and prioritization of assets within their portfolio. As such, Geron has regained the global rights to develop and commercialize imetelstat, a first-in-class telomerase inhibitor." Later that day, MarketWatch reported that "[s]hares of Geron Corp. GERN plummeted 63% to pace all premarket decliners, after the biopharmaceutical company said Janssen Biotech Inc. has terminated its collaboration and license agreement (CLA), following a strategic portfolio evaluation and prioritization of assets."
If you are aware of any facts relating to this investigation, or purchased Geron shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/gern. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC